Aurora, CO, September 13, 2004. GlobeImmune, Inc. today announced the appointment of Dr. Paul Bunn to its Scientific Advisory Board.
Dr. Bunn is the Grohne-Stapp Endowed Professor of Oncology Research and Director of the University of Colorado Cancer Center in Aurora, Colorado. He is also Executive Director of the International Association for the Study of Lung Cancer (IASLC). Dr. Bunn’s research interests are in the biology, diagnosis, prevention and treatment of lung cancer. Prior to 1984, he headed the Cell Kinetic Section of the National Cancer Institute. He has served as President of the American Society of Clinical Oncology (ASCO), President of the American Association of Cancer Institutes, President of the IASLC, and Chairman of the FDA Oncology Drug Advisory Committee. He received a BA in Biology from Amherst College and his MD from Cornell University Medical Center. He completed his residency at the University of California, San Francisco and his fellowship in Medical Oncology at the Medicine Branch of the National Cancer Institute. He has published over 230 articles in peer reviewed journals, 108 reviews, and 90 book chapters.
“We are pleased to welcome Dr. Bunn to our Advisory Board and look forward to bringing his expertise in clinical oncology to the successful development and commercialization of our Immunotherapies” said Timothy C. Rodell, M.D., GlobeImmune’s Chief Executive Officer. Dr. Bunn joins existing Advisors Teresa Brentnall, M.D., Edgar Engleman, M.D., Edward Mocarski, Ph.D., Alan Venook, M.D. and Bruce Walker, M.D.
About GlobeImmune
GlobeImmune, Inc. is an early-stage biopharmaceutical company pioneering the development of potent, targeted molecular immunotherapies for the treatment of cancer and infectious diseases. The Company’s first products for the treatment of cancers of the lung and gastrointestinal tract are currently in Phase 1 clinical trials. For additional information, please visit the company’s website at https://globeimmune.com/ . GlobeImmune is headquartered at the Fitzsimons BioScience Park in Aurora, Colorado.
Contact:
Timothy C. Rodell, M.D, CEO
GlobeImmune, Inc.
720-859-4070